| Closed Market –
22:00:00 01/07/2024 | Varies. 5j. | Varia. Jan 1 | ||
| 24,27 | -10,14 % | +5,34 % | +17,35 % | |
July 02, 2024 at 12:35 PM
Cartesian Therapeutics said on Tuesday that its experimental treatment for autoimmune diseases has met the primary endpoint of a mid-stage study. (Reporting by Sneha SK in Bengaluru; Editing by Shailesh Kuber)
Go to the original article.
Legal Disclaimer
Legal Disclaimer
Contact us for any correction requests
© Reuters – 2024
| Cartesian Therapeutics’ autoimmune disease treatment meets primary endpoint of mid-stage study | 12:35 | RE |
| Swedish company Sobi files US marketing authorization for gout treatment | 10:41 | MT |
| Sobi Files Biologics License Application with FDA for SEL-212 for Potential Treatment of Refractory Chronic Gout | 08:27 | CI |
| CARTESIAN THERAPEUTICS, INC. : Opinion positive de Oppenheimer | 04/06 | ZM |
| CARTESIAN THERAPEUTICS, INC. : Mizuho Securities toujours positif | 24/05 | ZM |
| Cartesian Obtains Advanced Therapy in Regenerative Medicine Designation for Its Myasthenia Gravis Drug Candidate | 22/05 | MT |
| Cartesian Therapeutics, Inc. Receives Regenerative Medicine Advanced Therapy Designation from FDA for Descartes-08 for the Treatment of Myasthenia Gravis | 22/05 | CI |
| CARTESIAN THERAPEUTICS, INC. : Leerink Partners optimiste sur le dossier | 23/04 | ZM |
| Cartesian Therapeutics, Inc. Receives Notice from Audentes Therapeutics, Inc. Regarding Termination of Astellas License Agreement ? Termination of License and Development Agreement | 14/03 | CI |
| Cartesian Therapeutics, Inc. Announces Results for the Year Ended December 31, 2023 | 07/03 | CI |
| Cartesian Therapeutics, Inc. Announces the Resignation of Aymeric Sallin as a Member of the Board of Directors and Member of the Compensation Committee | 05/03 | CI |
| Cartesian Therapeutics, Inc. establishes its new headquarters and mRNA-based cell therapy manufacturing facility in Frederick, Maryland. | 05/03 | CI |
| Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Descartes-08, Lead mRNA Cell Therapy Candidate, in Patients with Myasthenia Gravis | 08/01 | CI |
| Cartesian Therapeutics, Inc. Announces Resignation of Scott D. Myers as Member of Board of Directors, Compensation Committee and Nominating and Corporate Governance Committee | 27/11 | CI |
| Selecta Biosciences, Inc. Announces Results for the Third Quarter and Nine Months Ended September 30, 2023 | 13/11 | CI |
| Sector Update: Healthcare stocks gain in late afternoon trading | 13/11 | MT |
| Selecta Biosciences merges with Cartesian Therapeutics | 13/11 | MT |
| Transcript : Cartesian Therapeutics, Inc., Selecta Biosciences, Inc. – M&A Call | 13/11 | |
| Cartesian Therapeutics, Inc. has acquired Selecta Biosciences, Inc. (NasdaqGM:RNAC) in a reverse merger transaction. | 13/11 | CI |
| Selecta Biosciences, Inc. and Swedish Orphan Biovitrum AB (Publ.) Enter into Amendment No. 1 to the License and Development Agreement | 31/10/23 | CI |
| Peter Traber, Chief Medical Officer of Selecta Biosciences, Inc. transitions to part-time Chief Medical Officer, effective November 6, 2023 | 31/10/23 | CI |
| SELECTA BIOSCIENCES, INC. : Mizuho Securities still positive | 18/08/23 | ZM |
| SELECTA BIOSCIENCES, INC. : Needham & Co. à l’achat | 18/08/23 | ZM |
| Transcript : Selecta Biosciences, Inc., Q2 2023 Earnings Call, Aug 17, 2023 | 17/08/23 | |
| Selecta Biosciences, Inc. Announces Results for the Second Quarter and Six Months Ended June 30, 2023 | 17/08/23 | CI |
Duration Auto. 2 months 3 months 6 months 9 months 1 an 2 ans 5 ans 10 ans Max.
Period Jour Week
More graphics
Cartesian Therapeutics, Inc. is a clinical-stage company developing messenger ribonucleic acid (mRNA)-based cell therapies for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA-based cell therapies for autoimmune diseases. Its lead asset, Descartes-08, is an autologous chimeric antigen receptor T-cell therapy (CAR-T) directed against B cell maturation antigen (BCMA), which the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation autologous CAR-T directed against BCMA mRNA. Through its proprietary technology and manufacturing platform, Descartes-15 has been designed to be more resistant than Descartes-08 to CAR recycling upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key factors in the pathogenesis of autoimmunity.
More information about the company
Purchase
Average recommendation
ACHETER
Last Closing Price
24,27
USD
Average Course Target
43,83
USD
Deviation / Average Target
+80,61 %
Consensus
| Varia. Jan 1 | Capi. | |
|---|---|---|
| +17,35 % | 432 M | |
| +15,82 % | 122 Md | |
| +20,35 % | 114 Md | |
| +18,22 % | 25,71 Md | |
| -25,31 % | 19,02 Md | |
| -20,74 % | 15,83 Md | |
| -19,67 % | 15,32 Md | |
| -46,87 % | 14,88 Md | |
| +62,55 % | 14,82 Md | |
| +6,34 % | 14,1 Md |
Biotherapeutic drugs
